Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: Toxicological and pathological implications

AIDS

Volumn 11, Issue 14, 1997, Pages 1689-1697

  Walmsley, Sharon L ^a   Winn, Louise M ^b   Harrison, Maureen L ^b   Uetrecht, Jack P ^a,b   Wells, Peter G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse drug reactions; Disulphides; Drug hypersensitivity reactions; Glutathione; Oxidative stress; Reactive oxygen species; Thiols; Trimethoprim sulphamethoxazole

Indexed keywords

CYSTEINE; DISULFIDE; GLUTATHIONE; SULFONAMIDE; THIOL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PLASMA; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; CYSTEINE; DISULFIDES; DRUG HYPERSENSITIVITY; GLUTATHIONE; GLUTATHIONE DISULFIDE; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; OXIDATIVE STRESS; SULFONAMIDES;

EID: 0030831664     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199714000-00005     Document Type: Article

References (53)

1. Larsson A, Orrenius S, Holmgren A, Mannervik B (Eds): Function of Glutathione: Biolchemical, Physiological, Toxicological, and Clinical Aspects. New York: Raven Press; 1983.
2. Rieder MJ, Uetrecht JP, Shear NH, Spielberg SP: Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1985, 224:724-728.
3. Rieder MJ, Uetrecht JP, Shear NH, et al.: Diagnosis of sulfonamide hypersensitivity reactions by in-vilro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989, 110:286 289.
4. Nelson SD: Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 1995, 27:147 177.
5. Meisler A: Metabolism and transport of glutathione and other γ-glutamyl compounds. In Function of Glutathione: Biolchemical, Physiological, Toxicological, and Clinical Aspect. Edited by Larsson A, Orrenius S, Holmgren A, Mannervik B. New York: Raven Press; 1988:1-22.
6. Sies H: Oxidative stress: from basic research to clinical application. Am J Med 1991, 91 (suppl 3C):S31-S38.
7. Halliwell B, Gutteridage JMC: Free Radicals in Biology and Medicine, 2nd edn. Oxford: Claredon Press; 1989.
8. Gilberl HF: Thermodynamic and kinetic constraints on thiol/disulfide exchange involving glutathione redox buffers. In Glutathione Centennial. Edited by Taniguchi N, Higashi T, Sakamoto Y, Meisrer A. New York: Academic Press; 1989:73-87.
9. Ames BN: Endogenous oxidalive DNA damage, aging and cancer. Free Rad Res Commun 1989, 7:121 128.
10. Legrand-Poels S, Vaira D, Pincemail I, Van der Vorst A, Pietle J: Activation of human immunodeficiency virus type 1 by oxidative stress. AIDS Res Hum Retroviruses 1990, 6:1889 1897.
11. Staal FJT, Roederer M, Herzenberi; LA. Herzenberg LA: Intracellular thiols regulate activation of nuclear factor kB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990, 87:9943 9947.
12. Papadopulos-Eleopulos F, Turner VF, Papadimitriou JM: Oxidative stress, HIV and AIDS. Res Immunol 1992, 143:145-148.
13. Greenspan HC, Arouma O: Could oxidative stress initiate programmed cell death in HIV infection? A role for plant derived metabolites having synergistic antioxidant activity, Chem Biol Interact 1994, 91:187 197.
14. Powis G, Briehl M, Oblong J: Redox signalling and the control of cell growth and death. Pharmacol Ther 1995, 68: 149-173.
15. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996, 10:709 720.
16. Gordin FM, Simon GL, Wofsy CB, Mills J: Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:495-499.
17. Fck HP, Gmunder H, Hartmann M, et al.: Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. Biol Chem Hoppe-Seyler 1989, 370:101-108.
18. Buhl R, Holroyd KJ, Mastrangeli A, et al.: Systemic glutathione deficiency in symptom free HIV-seropositive individuals. Lancet 1989, ii:1294-1298.
19. Giorgi G, Micheli L, Fiaschi AI, et al.: L-2-oxothiazolidine-4-carboxylic acid and glutathione in human immunodeficiency virus. Can Ther Res 1992, 52:461-468.
20. Staal FJT, Roederer M, Israelki DM, et al.: Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res Hum Retroviruses 1992, 8:305-311.
21. Holroyd KJ, Buhl R, Borok Z, et al.: Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax 1993, 48:985-989.
22. Pirmohamed M, Williams D, Tingle MD, et al.: Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996, 10:501-507.
23. Witschi A, Junker E, Schranz C, Speck RF, Lauterburg BH: Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res Hum Retroviruses 1995, 11:141 143.
24. Ankrust P, Svardal AM, Muller F, et al.: Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1995, 1:258-267.
25. Centers for Diseases Control: AIDS surveillance case definition for adolescence and adults. MMWR 1992, 41:1 9.
26. Reed DJ, Babson JR, Bealty PW, et al.: High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides. Anal Biochem 1980, 106:55-62.
27. Lash LH, Jones DP: Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma. Arch Biochem Biophys 1985, 240:583 592.
28. Helbliing B, Von Overback J, Lauterburg BH: Decreased synthesis of glutathione in patients with AIDS [abstract]. Eur J Clin Invest 1994, 24:A38.
29. Meister A: Glutathione metabolism and its selective modification, J Biol Chem 1988, 263:17205-17208.
30. Van der Ven AJ, Miei P, Peters WH, et al.: Monochlorobimane does not selectively label glutathione in peripheral blood mononuclear cells. Anal Biochem 1994, 217:41 47.
31. Kinscherf R, Fischhbach T, Mihni S, et al.: Effect of glutathione depletion and oral N-acetylcysteine treatment on CD4+ and CD8+ cells. FASEB J 1994, 8:448-451.
32. Lah de Virtal J, Maury CPG, Feppo A-M, Repo H: Elevated levels of circulating cachectin/tumour necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988, 85:289 291.
33. Poli G, Fauci AS: The role of monocyte/macrophages and cytoklnes in the pathogenesis of HIV infection. Pathbiology 1992, 60:246-251.
34. Meister A, Anderson ME: Glutathione. Annu Res Biochem 1983, 52:711 760.
35. Gmunder H, Fck HP, Benninghoff B, Roth S, Droge W: Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell Immunol 1990, 129:32-46.
36. Droge W, Murthy KK, Stahl-Hennig C, et al.: Plasma amino acid dysregulation after lentiviral infection. AIDS Res Hum Retroviruses 1993, 9:807-809.
37. Brigelius K: Mixed disulfides: biological functions and increase in oxidative stress. In Oxidative Stress. Edited by Sies H. London: Academic Press; 1985:243-272.
38. Gregus Z, Klaassen CD: Mechanisms of toxicity. In Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn. Edited by Klaassen CD. New York: McGraw-Hill: 1996:35-74.
39. Van der Ven AJ, Koopmans PP, Vree TB, Van der Meer JW: Adverse reactions to co-trimoxazole in HIV infect. Lancet 1991, 338:431-433.
40. Robinson MK, Rodrick ML, Jacobs DO, et al.: Glutathione depletion in rats impairs T-cell and macrophage immune function. Arch Surg 1993, 128:29-35.
41. Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA: Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 1990, 87:4884-4888.
42. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB: Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989, 86:5974-5978.
43. Roederer M, Ela SW, Staal FJT, Herzenberg LA, Herzenberg LA: N-acetylcysteine: a new approach to anti-HIV therapy. AIDS Res Hum Retroviruses 1992, 8:209-217.
44. Malorni W, Rivabene R, Santini MT, Donelli G: N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells. FEBS Latt 1993, 327:75-78
45. Roederer M, Staal FJT, Ela SW, Herzenberg LA, Herzenberg LA: N-acetylcysteine: potential for AIDS therapy. Pharmacology 1993, 46:121-129.
46. de Quay B, Malinverni R, Lauterburg BH: Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 1992, 6:815-819.
47. Kalebic T, Kinter A, Poli G, et al.: Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA 1991, 88:986-990.
48. Lioy J, Ho W-Z, Cutilli JR, Polin RA, Douglas SD: Thiol suppression of human immunodeficiency virus type 1 replication in primary cord blood monocyte-derived macrophages in vitro. J Clin Invest 1993, 91:495-498.
49. Kinter AL, Poli G, Fauci AS: N-acelylcysteine is a potent suppressor of human immunodeficiency virus transcription in persistently infected cells. Trans Assoc Am Physicians 1992, 105:36-43.
50. Roederer M, Raju PA, Staal FJT, Herzenberg LA, Herzenberg LA: N-acetylcysteine inhibits latent HIV expression in chronically infected cells. AIDS Res Hum Retroviruses 1991, 7:563-567.
51. Olsson B, Johansson M, Gabrielsson J, Bolme P: Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988, 34:77-82.
52. Holdiness MR: Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991, 20:123-134.
53. Kalayjian RC, Skowron G, Emgushiv RT, et al.: A Phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects. J Acquir Immune Defic Syndr 1994, 7:369-374.